# Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102

> **NCT04600284** · PHASE1 · COMPLETED · sponsor: **Addpharma Inc.** · enrollment: 25 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** AD-2101
- **DRUG:** AD-2102
- **DRUG:** AD-2101 + AD-2102

## Key facts

- **NCT ID:** NCT04600284
- **Lead sponsor:** Addpharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-16
- **Primary completion:** 2021-01-20
- **Final completion:** 2021-04-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04600284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04600284, "Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04600284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*